Previous 10 | Next 10 |
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its develop...
- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET - - Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the ...
2023-10-31 12:41:14 ET More on Cybin Cybin Inc. 2023 FQ1 - Results - Earnings Call Presentation Cybin spikes after patent win Psychedelic drug developer Cybin completes acquisition of Small Pharma Seeking Alpha’s Quant Rating on Cybin Historica...
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced phase 2 interim results for CYB003, its proprietary de...
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 Canada NewsWire - Int...
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. p...
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the European Patent Office (“EP”) has granted...
- European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated DMT programs - - New European patent further strengthens intellectual property portfolio, which now includes 33 granted patents and ...
2023-10-25 10:13:59 ET More on Cybin Cybin Inc. 2023 FQ1 - Results - Earnings Call Presentation Psychedelic drug developer Cybin completes acquisition of Small Pharma Psychedelic drugs market to break $7B in 2029 led by these 3 meds Seeking Alpha’s Qua...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...